Novo Nordisk: CagriSema is superior to semaglutide in terms of weight loss and reduction of glycosylated hemoglobin.

Novo Nordisk today announced the core results of the phase 3 trial REIMAGINE 2 in the global REIMAGINE clinical trial program. The trial results showed that at week 68, for all tested doses, CagriSema was superior to semaglutide in reducing levels of glycosylated hemoglobin and weight loss. Compared to single-component drugs, CagriSema demonstrated superior efficacy in both weight loss and reduction of glycosylated hemoglobin. In this clinical trial, CagriSema showed good safety and tolerability, consistent with the characteristics of therapies based on incretin and amylin.